Abstracts tagged "Autoantibodies and dermatomyositis"

Abstract Number: 1259 • 2014 ACR/ARHP Annual Meeting
A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody
Shinji Sato¹, Akihiro Murakami², Akiko Kuwajima³, Kazuhiko Takehara⁴, Tsuneyo Mimori⁵, Atsushi Kawakami⁶, Michiaki Mishima⁷, Takafumi Suda⁸, Mariko Seishima⁹, Manabu Fujimoto¹⁰ and Masataka Kuwana¹¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ²Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, ³Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, ⁴Dermatology, Kanazawa University, Kanazawa, Japan, ⁵Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁶Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁸Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁹Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, ¹⁰Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) antibody is found specifically in patients with dermatomyositis (DM). This autoantibody is associated with clinically amyopathic DM (CADM) and…
Abstract Number: 1258 • 2014 ACR/ARHP Annual Meeting
Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity
Manabu Fujimoto¹, Akihiro Murakami², Shunsuke Kurei², Akiko Kuwajima³, Yasuhiro Fujisawa¹, Atsushi Kawakami⁴, Michiaki Mishima⁵, Shinji Sato⁶, Mariko Seishima⁷, Takafumi Suda⁸, Tsuneyo Mimori⁹, Kazuhiko Takehara¹⁰ and Masataka Kuwana¹¹, ¹Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, ³Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁶Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ⁷Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, ⁸Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁹Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ¹⁰Dermatology, Kanazawa University, Kanazawa, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Anti-transcriptional intermediary factor 1 (TIF-1) and anti-Mi-2 antibodies (Abs) are myositis-specific autoantibodies (MSA) selectively detected in dernatomyositis (DM) patients. Anti-TIF-1 Ab is frequently found…
Abstract Number: 1953 • 2012 ACR/ARHP Annual Meeting
Antibodies to NXP-2 and Transcriptional Intermediary Factor-Gamma Identify Patients with Cancer-Associated Dermatomyositis
David Fiorentino¹, Lisa Christopher-Stine², Lorinda Chung³, Bharathi Lingala⁴, Andrew L. Mammen⁵, Antony Rosen⁶ and Livia Casciola-Rosen⁶, ¹Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ⁴Dermatology, Stanford University, Redwood City, CA, ⁵NIAMS, NIH, Bethesda, MD, ⁶Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is known to be associated with internal malignancy, and identifying patients at high risk is a high priority. Recently, several groups have…
Abstract Number: 1954 • 2012 ACR/ARHP Annual Meeting
Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients
David Fiorentino¹, Lorinda Chung², Lisa Zaba¹, Bharathi Lingala³, Antony Rosen⁴ and Livia Casciola-Rosen⁴, ¹Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ³Dermatology, Stanford University, Redwood City, CA, ⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Myositis-specific antibodies have been proposed as tools for disease classification as they are correlated with certain clinical and genetic features. Recently, two new DM-specific…
Abstract Number: 226 • 2012 ACR/ARHP Annual Meeting
Autoantibodies to Small Ubiquitin-Like Modifier Activating Enzymes in Japanese Patients with Dermatomyositis
Manabu Fujimoto¹, Takashi Matsushita², Yasuhito Hamaguchi³, Kenzo Kaji³, Minoru Hasegawa¹ and Kazuhiko Takehara⁴, ¹Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ²Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ³Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁴Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Myositis-specific autoantibodies (MSAs) are closely associated with distinct clinical subsets within idiopathic inflammatory myopaties, and thus serve as useful diagnostic tools. Recently, anti-small ubiquitin-like modifier…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].